Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Su, Haoran ^a   He, Min ^a   Li, Hongmei ^a   Liu, Qing ^a,b   Wang, Jia ^a   Wang, Yiqian ^a   Gao, Weiwei ^a   Zhou, Ling ^a   Liao, Jiayu ^a,c   Young, Andrew A ^a,d   Wang, Ming Wei ^a,b  

^a National Center for Drug Screening   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c University of California Riverside   (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BOC5; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN; BOC5 COMPOUND; CYCLOBUTANE DERIVATIVE; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLYCOSYLATED HEMOGLOBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; STOMACH EMPTYING; TREATMENT DURATION; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; METABOLISM; REFERENCE VALUE;

ANIMALIA; MUS;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CYCLOBUTANES; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; MICE; MICE, INBRED C57BL; RECEPTORS, GLUCAGON; REFERENCE VALUES; WEIGHT LOSS;

EID: 51449083777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002892     Document Type: Article

References (54)

1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
2. Lutsey PL, Steffen LM, Stevens J (2008) Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation 117: 754-761.
3. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR (1966) Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1: 1336-1337.
4. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, et al. (1985) Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75: 809-817.
5. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, et al. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29: 139-153.
6. Stonehouse A, Guan X, Holcombe J, Okerson T, Kendall D (2007) 3.5 years of exenatide maintained progressive weight reduction was associated with improvements in cardiovascular risk factors in patients with type 2 diabetes (T2DM). Obesity (Silver Spring): Abstract 271-P.
7. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, et al. (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29: 1263-1268.
8. Centers for Disease Control and Prevention. (CDC) (2006) State-specific prevalence of obesiLy among adults-United States, 2005. MMWR Morb Mortal Wkly Rep 55: 985-988.
9. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619.
10. Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, et al. (1997) Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46: 715-749.
11. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Mocaca mulatta). Diabetes 48: 1026-1034.
12. Young A (2005) Amylin and the integrated control of nutrient influx. Adv Pharmacol 52: 67-77.
13. Berger W, Caduff F. Pasquel M, Rump A (1986) The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984. Schweiz Med Wochenschr 116: 145-151.
14. Pederson RA, Schubert HE, Brown JC (1975) The insulinotropic action of gastric inhibitory polypeptide. Can J Physiol Pharmacol 53: 217-223.
15. 2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45: 1-3.
16. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
17. Irwin N, Green BD, Gault VA, Harriot P, O'Harte FP, et al. (2006) Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp Gerontol 41: 151-156.
18. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, et al. (2002) Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 10: 1008-1015.
19. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, et al. (2007) DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 143: 97-103.
20. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, et al. (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56: 8-15.
21. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493.
22. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104: 937-912.
23. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, et al. (2007) Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17: 5172-5478.
24. Chen D, Liao J, Li N, Zhou C, Liu Q, et al. (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/ db mice. Proc Natl Acad Sci USA 104: 943-948.
25. Harris RB (1999) Parabiosis between db/db and ob/ob or db/+ mice. Endocrinology 140: 138-145.
26. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
27. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, et al. (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905.
28. Tang-Christensen M, Vrang N, Mollet A, Gilg S, Lykkegaard K-A, et al. (2002) Peripheral administration of exendin-4 activates neurons in hindbrain and forebrain areas and causes the formation of a conditioned taste aversion. 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC. Program No. 775.5.
29. Young AA, Gedulin B, Vine W, Percy A, Rink TJ (1995) Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642-618.
30. 2. Eur J Pharmacol 269: 183-191.
31. Rabinovitch A, Gutzeit A, Renold AE, Cerasi E (1975) Insulin secretion in the spiny mouse (Acomys cahirinus). Dose and time kinetic studies with glucose in vivo and in vitro. Diabetes 24: 1094-1100.
32. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, et al. (2005) Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076.
33. Lee S, Muniyappa R, Yan X, Chen H, Yuc LQ, et al. (2008) Comparison between surrogate indexes or insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 294: E261-270.
34. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2102-2410.
35. Young A (2002) Glucagon-like Peptide-1, Exendin and Insulin Sensitivity. In: Hansen B, Shafrir E, eds (2002) Insulin Resistance and Insulin Resistance Syndrome. New York: Taylor and Francis, London. pp 235-262.
36. Maggs D, MacConell L, Zhuang D, Schnabel C, Taylor K, et al. (2006) Safety and effects on a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Diabetologia 49(suppl 1): 3-4. Abstract 0002.
37. Hui H, Farilla L, Merkel P, Perfetti R (2002) The short half-file or glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146: 863-869.
38. Ahren B, Pacini G (1999) Dose-related effects or GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol 277: E996-E1004.
39. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, et al. (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232.
40. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
41. Unger RH, Zhou YT, Orci L (1999) Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 96: 2327-2332.
42. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J (2006) Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 84: 556-560.
43. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181.
44. Nielsen L, Guan X, Bowlus C, Holcombe J, Maggs D, et al. (2007) Exenatide improved markers of hepatic function over 3 years in patients with type 2 diabetes. Diabetes 56(suppl 1): A149-A150. Abstract 561-P.
45. Rachman J, Barrow BA, Levy JC, Turner RC (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211.
46. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322.
47. Parkes D, Kendall E, Reynolds J, Hargrove D, Gedulin B, et al. (2005) Insulinotropic action of exenatide (exendin-4) abates during hypoglycemia in rats. Diabetes 54(suppl 1): A368. Abstract 1523-P.
48. Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273.
49. Han GC, Ko SK, Sung JH, Chung SH (2007) Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. J Agric Food Chem 55: 10641-10648.
50. Macdonald IA (1996) Physiological regulation of gastric emptying and glucose absorption. Diabet Med 13: S11-15.
51. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395: 763-770.
52. Young A (2007) Peptide drugs for metabolic diseases: amylin and GLP-1 agonists. In: Kangawa K, Minamino N, eds (2007) Peptide and Drug Discovery. Osaka: Japan Medical Do Co Ltd. pp 272-282.
53. Bonora E, Moghetti P, Zancanaro, C, Cigolini M, Querena M, et al. (1989) Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68: 374-378.
54. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756.